Coadministration of Lidocaine and Recombinant Human Erythropoietin-Beta

Effect on Pain and of Erythropoietin Pharmacokinetics

Shigeki Yamada, Isao Muraoka, Kana Kato, Rie Hiramatsu, Hiroko Ida, Hirohisa Kawahara, Toshitaka Nabeshima

Research output: Contribution to journalArticle

Abstract

Background: Subcutaneous injections of recombinant human erythropoietin is associated with significant pain at the injection site. The present study evaluated whether lidocaine reduces the pain associated with subcutaneous injection of recombinant human erythropoietin-beta (rhEPO-β) and whether coadministration of lidocaine alters the pharmacokinetics of erythropoietin. Methods: Fifteen hundred units of rhEPO-β (Epogen) or a combination of 1500 units of rhEPO-β and 0.1 mL of 1% lidocaine (Xylocaine) were administered subcutaneously to 4 study subjects. After injections, pain reduction was assessed using visual analog scale (VAS). Blood samples were collected at designated intervals to measure serum erythropoietin (EPO) concentrations. The pharmacokinetic parameters such as area under the serum concentration-time curve (AUC 0-48), peak concentration (C max), time to the C max (t max), and terminal elimination half-life (t1/2) were calculated by the usual methods. Results: The values of VAS were 8.3 ± 2.3 and 1.7 ± 1.2 for rhEPO-β alone and the combination with lidocaine, respectively, indicating that injection pain caused by rhEPO-β was reduced by the coadministration of lidocaine. The value of AUC 0-48 was 471.2 ± 176.7 (mean ± SD) mIU.mL/h for rhEPO-β and 675.1±292.0 mIU.mL/h for the combination; the value of C max was 15.3 ± 3.7 mIU/mL for rhEPO-β and 24.2 ± 8.8 mIU/mL for the combination. The value of t max was 27.75 ± 23.41 h and 10.50 ± 3.87 h for the combination, and the t 1/2 value was 17.91 ± 0.30 h for rhEPO-β and 37.10±10.32 h for the combination. However, no significant differences in the pharmacokinetic parameters of EPO were observed between rhEPO-β injection with or without lidocaine. Conclusion: No significant differences in the bioavailability parameters were observed between rhEPO-β alone and the combination of rhEPO-β and lidocaine. Coadministration of lidocaine seems to be effective for pain caused by subcutaneous injection of rhEPO-β without causing any problems in clinical safety.

Original languageEnglish
Pages (from-to)429-433
Number of pages5
JournalJournal of Applied Research
Volume3
Issue number4
Publication statusPublished - 01-09-2003
Externally publishedYes

Fingerprint

Erythropoietin
Lidocaine
Pharmacokinetics
Pain
Subcutaneous Injections
Injections
Epoetin Alfa
Visual Analog Scale
Area Under Curve
Serum
Biological Availability
Half-Life

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmacology

Cite this

Yamada, Shigeki ; Muraoka, Isao ; Kato, Kana ; Hiramatsu, Rie ; Ida, Hiroko ; Kawahara, Hirohisa ; Nabeshima, Toshitaka. / Coadministration of Lidocaine and Recombinant Human Erythropoietin-Beta : Effect on Pain and of Erythropoietin Pharmacokinetics. In: Journal of Applied Research. 2003 ; Vol. 3, No. 4. pp. 429-433.
@article{c73e028b76c34981b60164d8795e0d8a,
title = "Coadministration of Lidocaine and Recombinant Human Erythropoietin-Beta: Effect on Pain and of Erythropoietin Pharmacokinetics",
abstract = "Background: Subcutaneous injections of recombinant human erythropoietin is associated with significant pain at the injection site. The present study evaluated whether lidocaine reduces the pain associated with subcutaneous injection of recombinant human erythropoietin-beta (rhEPO-β) and whether coadministration of lidocaine alters the pharmacokinetics of erythropoietin. Methods: Fifteen hundred units of rhEPO-β (Epogen) or a combination of 1500 units of rhEPO-β and 0.1 mL of 1{\%} lidocaine (Xylocaine) were administered subcutaneously to 4 study subjects. After injections, pain reduction was assessed using visual analog scale (VAS). Blood samples were collected at designated intervals to measure serum erythropoietin (EPO) concentrations. The pharmacokinetic parameters such as area under the serum concentration-time curve (AUC 0-48), peak concentration (C max), time to the C max (t max), and terminal elimination half-life (t1/2) were calculated by the usual methods. Results: The values of VAS were 8.3 ± 2.3 and 1.7 ± 1.2 for rhEPO-β alone and the combination with lidocaine, respectively, indicating that injection pain caused by rhEPO-β was reduced by the coadministration of lidocaine. The value of AUC 0-48 was 471.2 ± 176.7 (mean ± SD) mIU.mL/h for rhEPO-β and 675.1±292.0 mIU.mL/h for the combination; the value of C max was 15.3 ± 3.7 mIU/mL for rhEPO-β and 24.2 ± 8.8 mIU/mL for the combination. The value of t max was 27.75 ± 23.41 h and 10.50 ± 3.87 h for the combination, and the t 1/2 value was 17.91 ± 0.30 h for rhEPO-β and 37.10±10.32 h for the combination. However, no significant differences in the pharmacokinetic parameters of EPO were observed between rhEPO-β injection with or without lidocaine. Conclusion: No significant differences in the bioavailability parameters were observed between rhEPO-β alone and the combination of rhEPO-β and lidocaine. Coadministration of lidocaine seems to be effective for pain caused by subcutaneous injection of rhEPO-β without causing any problems in clinical safety.",
author = "Shigeki Yamada and Isao Muraoka and Kana Kato and Rie Hiramatsu and Hiroko Ida and Hirohisa Kawahara and Toshitaka Nabeshima",
year = "2003",
month = "9",
day = "1",
language = "English",
volume = "3",
pages = "429--433",
journal = "Journal of Applied Research",
issn = "1537-064X",
publisher = "The Journal of Applied Research",
number = "4",

}

Coadministration of Lidocaine and Recombinant Human Erythropoietin-Beta : Effect on Pain and of Erythropoietin Pharmacokinetics. / Yamada, Shigeki; Muraoka, Isao; Kato, Kana; Hiramatsu, Rie; Ida, Hiroko; Kawahara, Hirohisa; Nabeshima, Toshitaka.

In: Journal of Applied Research, Vol. 3, No. 4, 01.09.2003, p. 429-433.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Coadministration of Lidocaine and Recombinant Human Erythropoietin-Beta

T2 - Effect on Pain and of Erythropoietin Pharmacokinetics

AU - Yamada, Shigeki

AU - Muraoka, Isao

AU - Kato, Kana

AU - Hiramatsu, Rie

AU - Ida, Hiroko

AU - Kawahara, Hirohisa

AU - Nabeshima, Toshitaka

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background: Subcutaneous injections of recombinant human erythropoietin is associated with significant pain at the injection site. The present study evaluated whether lidocaine reduces the pain associated with subcutaneous injection of recombinant human erythropoietin-beta (rhEPO-β) and whether coadministration of lidocaine alters the pharmacokinetics of erythropoietin. Methods: Fifteen hundred units of rhEPO-β (Epogen) or a combination of 1500 units of rhEPO-β and 0.1 mL of 1% lidocaine (Xylocaine) were administered subcutaneously to 4 study subjects. After injections, pain reduction was assessed using visual analog scale (VAS). Blood samples were collected at designated intervals to measure serum erythropoietin (EPO) concentrations. The pharmacokinetic parameters such as area under the serum concentration-time curve (AUC 0-48), peak concentration (C max), time to the C max (t max), and terminal elimination half-life (t1/2) were calculated by the usual methods. Results: The values of VAS were 8.3 ± 2.3 and 1.7 ± 1.2 for rhEPO-β alone and the combination with lidocaine, respectively, indicating that injection pain caused by rhEPO-β was reduced by the coadministration of lidocaine. The value of AUC 0-48 was 471.2 ± 176.7 (mean ± SD) mIU.mL/h for rhEPO-β and 675.1±292.0 mIU.mL/h for the combination; the value of C max was 15.3 ± 3.7 mIU/mL for rhEPO-β and 24.2 ± 8.8 mIU/mL for the combination. The value of t max was 27.75 ± 23.41 h and 10.50 ± 3.87 h for the combination, and the t 1/2 value was 17.91 ± 0.30 h for rhEPO-β and 37.10±10.32 h for the combination. However, no significant differences in the pharmacokinetic parameters of EPO were observed between rhEPO-β injection with or without lidocaine. Conclusion: No significant differences in the bioavailability parameters were observed between rhEPO-β alone and the combination of rhEPO-β and lidocaine. Coadministration of lidocaine seems to be effective for pain caused by subcutaneous injection of rhEPO-β without causing any problems in clinical safety.

AB - Background: Subcutaneous injections of recombinant human erythropoietin is associated with significant pain at the injection site. The present study evaluated whether lidocaine reduces the pain associated with subcutaneous injection of recombinant human erythropoietin-beta (rhEPO-β) and whether coadministration of lidocaine alters the pharmacokinetics of erythropoietin. Methods: Fifteen hundred units of rhEPO-β (Epogen) or a combination of 1500 units of rhEPO-β and 0.1 mL of 1% lidocaine (Xylocaine) were administered subcutaneously to 4 study subjects. After injections, pain reduction was assessed using visual analog scale (VAS). Blood samples were collected at designated intervals to measure serum erythropoietin (EPO) concentrations. The pharmacokinetic parameters such as area under the serum concentration-time curve (AUC 0-48), peak concentration (C max), time to the C max (t max), and terminal elimination half-life (t1/2) were calculated by the usual methods. Results: The values of VAS were 8.3 ± 2.3 and 1.7 ± 1.2 for rhEPO-β alone and the combination with lidocaine, respectively, indicating that injection pain caused by rhEPO-β was reduced by the coadministration of lidocaine. The value of AUC 0-48 was 471.2 ± 176.7 (mean ± SD) mIU.mL/h for rhEPO-β and 675.1±292.0 mIU.mL/h for the combination; the value of C max was 15.3 ± 3.7 mIU/mL for rhEPO-β and 24.2 ± 8.8 mIU/mL for the combination. The value of t max was 27.75 ± 23.41 h and 10.50 ± 3.87 h for the combination, and the t 1/2 value was 17.91 ± 0.30 h for rhEPO-β and 37.10±10.32 h for the combination. However, no significant differences in the pharmacokinetic parameters of EPO were observed between rhEPO-β injection with or without lidocaine. Conclusion: No significant differences in the bioavailability parameters were observed between rhEPO-β alone and the combination of rhEPO-β and lidocaine. Coadministration of lidocaine seems to be effective for pain caused by subcutaneous injection of rhEPO-β without causing any problems in clinical safety.

UR - http://www.scopus.com/inward/record.url?scp=2342604435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342604435&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 429

EP - 433

JO - Journal of Applied Research

JF - Journal of Applied Research

SN - 1537-064X

IS - 4

ER -